N
TXG icon

Nuveen’s 10x Genomics TXG Stock Holding History

Nuveen’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.3M Buy
625,796
+389,393
+165% +$7.78M ﹤0.01% 1390
2025
Q4 		$3.86M Buy
236,403
+7,875
+3% +$119K ﹤0.01% 2020
2025
Q3 		$2.67M Hold
228,528
– – ﹤0.01% 2179
2025
Q2 		$2.65M Buy
228,528
+27,467
+14% +$250K ﹤0.01% 2171
2025
Q1 		$1.76M Hold
201,061
– – ﹤0.01% 2387
2024
Q4 		$2.89M Sell
201,061
-73
-0% -$1.15K ﹤0.01% 2231
2024
Q3 		$4.54M Sell
201,134
-66,544
-25% -$1.38M ﹤0.01% 2033
2024
Q2 		$5.21M Buy
267,678
+15,378
+6% +$403K ﹤0.01% 1935
2024
Q1 		$9.47M Buy
252,300
+697
+0.3% +$30.6K ﹤0.01% 1623
2023
Q4 		$14.1M Buy
251,603
+61,981
+33% +$2.7M ﹤0.01% 1375
2023
Q3 		$7.82M Sell
189,622
-65,016
-26% -$3.38M ﹤0.01% 1619
2023
Q2 		$14.2M Sell
254,638
-1,998
-0.8% -$108K ﹤0.01% 1301
2023
Q1 		$14.3M Buy
256,636
+37,298
+17% +$1.74M 0.01% 1255
2022
Q4 		$7.99M Sell
219,338
-5,533
-2% -$181K ﹤0.01% 1636
2022
Q3 		$6.4M Sell
224,871
-9,830
-4% -$375K ﹤0.01% 1751
2022
Q2 		$10.6M Buy
234,701
+30,784
+15% +$1.6M ﹤0.01% 1464
2022
Q1 		$13.6M Buy
203,917
+7,845
+4% +$686K ﹤0.01% 1449
2021
Q4 		$29.2M Sell
196,072
-10,058
-5% -$1.54M 0.01% 999
2021
Q3 		$30M Sell
206,130
-449,489
-69% -$77.2M 0.01% 994
2021
Q2 		$128M Sell
655,619
-394,107
-38% -$71.3M 0.04% 400
2021
Q1 		$190M Sell
1,049,726
-31,019
-3% -$5.36M 0.06% 288
2020
Q4 		$153M Buy
1,080,745
+79,339
+8% +$11.5M 0.05% 324
2020
Q3 		$125M Buy
1,001,406
+681,250
+213% +$71.5M 0.05% 311
2020
Q2 		$27.1M Buy
+320,156
New +$24.9M 0.01% 857

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen's TXG Position: Q1 2026 in Review

Nuveen increased its 10x Genomics (TXG) stake by 165% in Q1 2026, buying an estimated $7.78M and bringing the position to 625,796 shares worth $13.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1390.

Nuveen first reported a position in TXG in Q2 2020 and has held it in 24 quarters since. The position peaked at $190M in Q1 2021. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Nuveen held 625,796 shares of 10x Genomics worth $13.3M as of Q1 2026.
  • Nuveen bought 389,393 10x Genomics shares in Q1 2026, an estimated $7.78M.
  • 10x Genomics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1390 holding.
  • Nuveen first reported a position in 10x Genomics in Q2 2020 and has held it in 24 quarters since.
  • Nuveen's 10x Genomics position peaked at $190M in Q1 2021.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.